Women’s Longevity Biomarkers Are Becoming More Sex-Specific

Women’s longevity biomarkers are entering a more precise phase. New cardiovascular guidance recognises that women can be missed when diagnostic thresholds are treated as universal, while comparative ageing research is identifying metabolic patterns associated with lifespan across species. Together, these developments point toward a more individual view of ageing, based on biological signals rather than chronological age alone.

That shift matters because women’s risk changes across the lifespan. Pregnancy complications, menstrual history and the menopause transition can all add information that conventional models overlook. Yet a biomarker is useful only when its meaning is established in women, interpreted in context and linked to an action that improves health.

Women’s longevity biomarkers must account for sex differences

Cardiovascular disease remains a major determinant of women’s healthspan and lifespan, but its diagnosis has historically been shaped by evidence generated disproportionately in men. The newly agreed universal definition of heart attack is therefore important not simply as a change in terminology, but as an attempt to make diagnosis more sensitive to different mechanisms and presentations.

According to reporting on the guidance, it expands recognition of overlooked causes and introduces sex-specific diagnostic thresholds. One central issue is cardiac troponin, a protein released into the blood when heart muscle is injured. Women generally have lower baseline and upper-reference troponin concentrations than men. A single pooled threshold can therefore classify clinically meaningful injury in a woman as normal.

Sex-specific thresholds are not a minor statistical adjustment. Earlier identification can affect monitoring, treatment and prevention after an acute event. It may also reduce a longstanding diagnostic gap created by the misconception that women’s heart attacks are fundamentally atypical. Chest discomfort remains common, although nausea, breathlessness, fatigue, back or jaw discomfort and less recognisable symptom combinations can complicate assessment.

For longevity care, the broader lesson is that reference ranges are not automatically neutral. A laboratory value can be technically accurate while its interpretation remains poorly calibrated to female physiology, age, hormonal stage or clinical history.

Metabolic fingerprints may reveal how ageing unfolds

Research from the Dog Aging Project offers a different window into longevity. Investigators found that patterns of small molecules circulating in dogs’ blood were associated with longer or shorter lifespans in ways that resembled findings in humans. These metabolites reflect interconnected processes including energy use, inflammation, cellular stress and nutrient handling.

Dogs are useful ageing models because they share homes, environmental exposures and some chronic diseases with people, while ageing over a shorter timescale. Similar metabolic associations across species can help researchers identify biological pathways worth testing more directly in humans. They cannot, however, establish a longevity test for clinical use.

The finding supports a move away from searching for one definitive ageing marker. Biological ageing is more likely to be represented by a profile that combines metabolic, inflammatory, cardiovascular and functional information. Common clinical measures such as blood pressure, lipids, glucose regulation and kidney function already capture parts of that profile. Newer metabolomic panels could eventually add resolution, but they need prospective validation across diverse populations.

Evidence in women also requires deliberate analysis. Menstrual cycling, pregnancy, hormonal contraception and menopause can alter metabolism and inflammation. A blood signature derived from mixed populations may perform differently across reproductive stages unless researchers test those differences explicitly.

Sleep supplements need the same long-term scrutiny

Sleep is closely tied to healthy ageing, cardiovascular function and metabolic regulation, but treating poor sleep with a supplement does not guarantee a longevity benefit. A large preliminary observational study reported that people with chronic insomnia who used melatonin over an extended period had a substantially higher rate of heart failure during five years of follow-up.

The reported association was close to a doubling of risk, but it does not show that melatonin caused heart failure. Long-term users may have had more severe insomnia, poorer underlying health, different medication exposure or other unmeasured risks. Supplement use can also be recorded incompletely, particularly where melatonin is available without prescription. The work is preliminary and requires peer-reviewed replication.

Even so, the signal challenges the assumption that an over-the-counter sleep aid is automatically suitable for indefinite use. Melatonin is a hormone involved in circadian timing, not simply a sedative. Dose, formulation, timing and product quality vary, and evidence for prolonged daily use is less robust than its popularity suggests.

This is relevant to women because sleep commonly changes during perimenopause and menopause, when hot flushes, mood symptoms, circadian shifts and sleep-disordered breathing can overlap. Repeatedly suppressing the symptom without identifying its driver may leave a treatable cardiovascular, respiratory or hormonal contributor unaddressed.

Function remains a practical measure of healthy ageing

Longevity is not captured by blood tests alone. The capacity to move without persistent pain, maintain strength and recover from activity is central to healthspan. Research involving more than 1,330 previously inactive women in social sport programmes found that around one in five experienced injury or pain affecting participation. Knees, lower backs and ankles were the most common sites, and injury-related barriers were more frequent among women from lower-income households.

The study does not argue against exercise. Physical activity remains one of the strongest modifiable supports for cardiovascular, metabolic, musculoskeletal and cognitive health. Instead, it shows why access alone is insufficient. Programmes designed to improve long-term activity need appropriate progression, strength development, recovery and realistic routes back after pain or injury.

Female-specific context can matter here too. Energy availability, iron status, cycle-related symptoms and the menopause-associated decline in oestrogen can influence training tolerance, muscle maintenance and bone health. These factors do not make women fragile, but they can change what effective progression and recovery look like.

Turning daily signals into a longer view

The emerging picture of women’s longevity is layered: more accurate cardiac thresholds, multidimensional metabolic profiles, closer scrutiny of chronic supplement use and functional measures that reflect life outside the clinic. No single score can yet integrate all of these reliably, and early biomarkers should not displace established prevention such as blood-pressure control, lipid assessment, resistance training, adequate sleep and avoiding tobacco exposure.

Sleep quality, energy, cycle or menopause symptoms, supplement response and training recovery only become readable when logged consistently over weeks. This is the kind of pattern Tulsy is built to surface.

Sources: The Guardian, ScienceDaily, Medical Xpress.

This content is for informational and educational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease, and should not replace advice from a qualified healthcare professional.